Reactivation of hepatitis B virus with rituximab

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 599-608

  Tsutsumi, Yutaka ^a   Kanamori, Hiroe ^a   Mori, Akio ^a   Tanaka, Junji ^b   Asaka, Masahiro ^b   Imamura, Masahiro ^b   Masauzi, Nobuo ^a  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatitis B virus (HBV); Lamivudine; Non Hodgkin's lymphoma (NHL); Reactivation; Rituximab

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS ANTIBODY;

AUTOIMMUNE DISEASE; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS B; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; NONHUMAN; PARVOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KINETICS; LAMIVUDINE; LYMPHOMA, NON-HODGKIN;

EID: 19444367030     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.599     Document Type: Review

References (74)

1. GALBRAITH RM, EDDLESTON AL, WILLIAMS R, ZUCKERMAN AJ, BAGSHAWE KD: Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet (1975) 2:538-530.
2. HOONFNAGLE JH, DUSHEIKO GM, SCHAFER DF et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. (1982) 96:447-449.
3. THUNG SN, GERBER MA, KLION F, GILBERT H: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch. Intern. Med. (1985) 145:1313-1314.
4. LAU JY, LAI CL, LIN HJ et al.: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart. J. Med. (1989) 73:911-917.
5. BIRD GL, SMITH H, PORTMANN B, ALEXANDER GJ, WILLIAMS R: Acute liver decompensation of withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Quart. J. Med. (1989) 73:895-902.
6. LIANG RHS, LOK ASF, LAI CL, CHAN TK, TODD O, CHIU EKW: Hepatitis B infection in patients with lymphomas. Hematol. Oncol. (1990) 8:261-270.
7. LOK ASF, LAI CL, WU PC: Hepatitis B virus infection in Chinese families in Hong Kong. Am. J. Epidemiol. (1987) 126:492-499.
8. LOK ASF, LIANG RHS, CHIU EKW, WONG KL, CHAN TK, TOOD D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology (1991) 100:182-188.
9. PINTO PC, HU E, BERNSTEIN-SINGER M, PINTER-BROWN L, GOVINDARAJAN S: Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer (1990) 65:878-884.
10. SOH LT, ANG PT, SNG I, CHUA EJ, ONG YW: Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur. J. Cancer (1992) 28A:1338-1339.
11. NAKAMURA Y, MOTOKURA T, FUJITA A, YAMASHITA T, OGATA E: Sever hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987-1991. Cancer (1996) 78:2210-2215.
12. KUMAGAI K, TAKAGI T, NAKAMURA S et al.: Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. (1997) 8:107-109.
13. YEO W, CHAN PKS, ZHONG S et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J. Med. Virol. (2000) 62:299-307.
14. MALONEY DG, LILES TM, CZERWINSKI DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84:2457-2466.
15. MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188-2195.
16. MALONEY DG, GRILLO-LOPEZ AJ, BODKIN D et al.: IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15:3266-3274.
17. MACLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833.
18. TOBINAI K, KOBAYASI Y, NARABAYASHI M et al., and Members of the IDCE-C2B8 study groupe. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in a relapsed B-cell lymphoma. Ann. Oncol. (1998) 9:527-534.
19. IGARASHI T, OHTSU T, FUJII H et al., and Members of the IDEC-C2B8 Study Group. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int. J. Hematol. (2001) 73:213-221.
20. COIFFER B, HAIOUN N, ENGERT KA et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92:1927-1932.
21. FORAN JM, ROHATINER AZS, CUNNINGHAM D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytome, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. (2000) 18:317-324.
22. DAVIS TA, WHITE CA, GRILLO-LOPEZ AJ et al.: Single-agent monoclonal antibody efficacy in bulkey non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J. Clin. Oncol. (1999) 17:1851-1857.
23. GHIELMINI M, HSH SCHMITZ SF, BURKI K et al.: The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol. (2000) 11:S123-S126.
24. KUNKEL L, WONG A, MANEATIS T et al.: Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update. Semin. Oncol. (2000) 27:53-61.
25. TOBINAI K: Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int. J. Hematol. (2002) 76:411-419.
26. IGARASHI T, KOBAYASHI Y, OGURA M et al.: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese Phase II study. Ann. Oncol. (2002) 13:928-943.
27. TOBINAI K, IGARASHI T, KOBAYASHI Y et al.: Japanese multicenter Phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann. Oncol. (2004) 15:821-830.
28. ROTHE A, SCHULZ H, ELTER T, ENGERT A, REISER M: Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica (2004) 89:875-876.
29. SEYMOUR JF: New treatment approaches to indolent non-Hodgkin's lymphoma. Semin. Oncol. (2004) 31:27-32.
30. CZUCZMAN MS, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. (2004) 22:4711-4716.
31. BERMUDEZ A, MARCO F, CONDE E, MAZO E, RECIO M, ZUBIZARRETA A: Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica (2000) 85:894-895.
32. SHARMA VR, FLEMING DR, SLONE S: Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood (2000) 96:1184-1186.
33. SUZAN F, AMMOR M, RIBRAG V: Fatal reactivation of cytomegalovirus infection after use of rituximab for a post transplantation lymphoproliferative disorder. N. Engl. J. Med. (2001) 345:1000.
34. GOLDBERG SL, PECORA AL, ALTER RS et al.: Unusual wiral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood (2002) 99:1486-1488.
35. CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low grade B-cell lymphoma with the combination of chemeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. (1999) 17:268-276
36. HERNANDEZ JA, DILOY R, SALAT D, DEL RIO N, MARTINEZ X, CASTELLVI JM: Fluminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica (2003) 88:ECR22.
37. SKRABS C, MULLER C, AGIS H, MANNHALTER C, JAGER U: Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia (2002) 16:1884-1886.
38. WESTHOFF TH, JOCHIMSEN F, SCHMITTEL A et al.: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 102:1930.
39. NG HJ, LIM LC: Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann. Hematol. (2001) 80:549-552.
40. JAGER G, NEUMEISTER P, BREZINSCHEK R et al.: Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a Phase II study. Eur. J. Haematol. (2002) 69:21-26.
41. DERVITE I, HOBER D, MOREL P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. (2001) 344:68-69.
42. ROSSINI F, CAPALBO S, FUMAGALLI M et al.: 'Standard dose' rituximab in refractory chronic lymphocytic leukemia. Hematol. J. (2002) 3(Suppl. 1) [0827].
43. DOMINGO-DOMENECH E, GONZALEZ-BARCA E, ESTANY C, SUREDA A, BESALDUCH J, DE SEVILLA AF: Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica (2002) 87:1229-1230.
44. TSUTSUMI Y, KAWAMURA T, SAITOH S et al.: Hepatitis B virus reactivation in a case of Non-Hodgkin's lymphoma treated with chemotherapy and rituximab (necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy). Leuk. Lymphoma (2004) 45:627-629.
45. TSUTSUMI Y, TANAKA J, KAWAMURA T et al.: Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann. Haematol. (2004) 83:58-60.
46. MIMIDIS K, TSATALAS C, MARGARITIS D et al.: Efficacy of lamivdine in patients with hamatologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol. (2002) 107:49-51.
47. HAMAKI T, KAMI M, KUSUMI E et al.: Prophylaxis of hapatitis B reactivation using lamivdine in a patient receiving rituximab. Am. J. Hematol. (2001) 68:292-294.
48. KAMI M, HAMAKI T, MURASHIGE N et al.: Safty of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol. J. (2003) 4:159-162.
49. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
50. UPRICHARD SL, WIELAND SF, ALTHAGE A, CHISARI FV: Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc. Natl. Acad. Sci. USA (2003) 100:1310-1315.
51. THIMME R, WIELAND S, STEIGER C et al.: CD8+ T-cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Viol. (2003) 77:68-76.
52. SHI TD, WU YZ, JIA ZC, ZOU LY, ZHOU W: Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J. Gastroenterol. (2004) 10:1902-1906.
53. COIFFER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346:235-242.
54. YOSHIBA M, SEKIYAMA K, INOUE K, FUJITA R: Interferon and cyclosporinA in the treatment of fulminant viral hepatitis. J. Gastroenterol. (1995) 30:67-73.
55. VENTO S, CAINELLI F, LONGHI MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. (2002) 3:333-340.
56. LAU GKK, YIU HHY, FONG DYT et al.: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology (2003) 125:1742-1749.
57. AL-TAIE OH, MORK H, GASSEL AM, WILHELM M, WEISSBRICH B, SCHEURLEN M: Prevention of hepatitis B flare-up during chemotherapy using lamivdine: case report and review of the literature. Ann. Hematol. (1999) 78:247-249.
58. SILVESTRI F, ERMACORA A, SPEROTTO A et al.: Lamivdine allows completion of chemotherapy in lymphoma patients with hapatitis B reactivation. Br. J. Haematol. (2000) 108:394-396.
59. SHIBOLET O, GILLIS S, HUBERT A, SHOUVAL D, SAFADI R: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood (2002) 100:391-396.
60. ESTEVE M, SARO C, GONZALEZ-HUIX F, SUAREZ F, FORNE M, VIVER JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 53:1363-1365.
61. PELIZZARI AM, MOTTA M, CARIANI E, TURCONI P, BORLENGHI E, ROSSI G: Frequency of hepatitis B virus mutant in asymptomatic hepatitis virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol. J. (2004) 5:325-328.
62. BRUNETTO MR, STEMLER M, SHODEL F et al.: Identification of HBV variants which cannot produce pre-core derived HbeAg and may be responsible for severe hepatitis. Ital. J. Gastroenterol. (1989) 21:151-154.
63. CARMA WF, JACYNA MR, HADZIYANNIS S et al.: Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet (1989) 2:588-591
64. Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Sci. USA (1991) 88:4186-4190.
65. MURASAWA H, UMEMOTO S, HIJIKATA M et al.: Latent hepatitis B infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology (2000) 31:488-495.
66. YEO W, ZEE B, ZHONG S et al.: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivatio in cancer patients undergoin cytotoxic chemotherapy. Br. J. Cancer (2004) 90:1306-1311.
67. LOK AS, HEATHCOTE EJ, HOOFNAGEL JH: Management of Hepatitis B 2000-Summary of a workshop. Gastroenterology (2001) 120:1828-1853.
68. LOK ASF, MCMAHON BJ: Chronic hepatitis B: update of recommendations. Hepatology (2004) 39:857-861.
69. LOK ASF, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225-1241.
70. DAI MS, CHAO TY, KAO WY, SHYU RY, LIU TM: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. (2004) 83:769-774.
71. PICARDI M, PANE F, QUINTARELLI C et al.: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica (2003) 88:1296-1303.
72. PETERS MG, HANN HW, MARTIN P et al.: Adeforvir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91-101.
73. PEREZ-ROLDAN F, GONZALEZ-CARRO P, VILLAFANEZ-GARCIA MC: Adeforvir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med. (2004) 352:310-311.
74. TILLMANN HL, WEDEMEYER H, MANNS MP: Treatment of hepatitis B in special patient groups: hemodialysis heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J. Hepatol. (2003) 39:S206-S211.